论文部分内容阅读
对 40例手术确诊的卵巢和子宫体癌患者 ,按期别及年龄配对分成 2组 ,各 2 0例 .A组(试验组 )接受化疗加云芝糖肽 .B组 (对照组 )单纯化疗 .观察两组治疗前后血免疫指标及生活质量指数的变化 .结果治疗前后 Karnofsky评分值 A组分别为 84± 9.6分及 90± 8.6分( P <0 .0 5) ,B组分别为 83± 9.2分及 80± 1 2 .8分 ( P >0 .0 5) ,治疗后 A组比 B组高 1 0分( P <0 .0 5) ;治疗后 A组和 B组的 CD+ 4 分别为 2 8.1 4± 4.1 0及 2 3.1 2± 3.97( P <0 .0 5) ;CD+ 4 /CD+ 8为 0 .96± 0 .1 7及 0 .75± 0 .2 1 ( P <0 .0 1 ) ;NK为 2 3.80± 4.90及 1 5.32± 3.90( P <0 .0 1 ) ,A组均明显高于 B组 .提示云芝糖肽能提高卵巢和子宫体癌患者的细胞免疫和生活质量
Forty patients with ovarian and endometrial cancer diagnosed by surgery were divided into two groups according to age and age, and 20 cases in each group. Group A (test group) received chemotherapy plus PSK. Group B (control group) was treated with chemotherapy alone. Observe the change of blood immune index and quality of life index before and after treatment. Results Karnofsky scores before and after treatment in group A were 84±9.6 points and 90±8.6 points (P<0.05), respectively, in group B were 83±9.2. Scores were 80±12.8 points (P > 0.05). After treatment, group A was 10 points higher than group B (P < 0.05). After treatment, CD + 4 of group A and B were 2 8.1 4 ± 4.1 0 and 2 3.1 2 ± 3.97 (P <0.05); CD + 4 /CD + 8 is 0 .96 ± 0 .17 and 0 .75 ± 0 .2 1 (P <0 .0 1) The NK was 2.80±4.90 and 1 5.32± 3.90 (P<0.01). The A group was significantly higher than that of the B group. It was suggested that PSK could improve the cellular immunity and life of patients with ovarian and endometrial cancer. quality